· Published by Health Canada · Official notice
This is duplicated text of a letter from Sanofi Pasteur Limited.
Contact the company for a copy of any references, attachments or enclosures.
July 13, 2012
Dear Health Care Professional
Subject: Supply status of ImmuCyst® [Bacillus Calmette-Guérin (BCG), sub strain Connaught]
Sanofi Pasteur halted distribution of ImmuCyst® in April 2012 because the validation of one of the required release tests that confirms the sterility of the product failed to demonstrate an acceptable ability to detect mould and yeast. Additionally, environmental monitoring in the BCG production facility showed an increasing level of microorganisms, including mould in the facility. To fully address this situation, in consultation with regulatory authorities, Sanofi Pasteur has decided to renovate the facility and has temporarily suspended production of BCG while renovations are made.
ImmuCyst® is indicated for intravesicular use in the treatment of primary or recurrent carcinoma in situ (CIS) of the urinary bladder, for prophylaxis of recurrence of CIS of the urinary bladder, and for prophylaxis following transurethral resection of primary or recurrent stage Ta and /or T1 papillary tumours, or any combination thereof, regardless of antecedent intravesicular treatment.
In consultation with Health Canada, it has been determined that the benefits of the product to patients outweigh the risk of potential microbial contamination. To date, there is no evidence of contamination in currently released lots of ImmuCyst® on the market, and there have been no reports of infections that might be caused by contamination in the post marketing adverse event surveillance. As a result, Sanofi Pasteur is not conducting a recall of ImmuCyst®.
Sanofi Pasteur recognizes and regrets the impact that this supply constraint may have on patients and their healthcare providers. Sanofi Pasteur understands the importance of ImmuCyst® in treating bladder cancer and we are committed to resuming manufacture of this product as quickly as possible. Our preliminary estimate forecasts resuming supply of ImmuCyst® in late 2013.
In Canada, there is another supplier of BCG product for the treatment of bladder cancer. However, Sanofi Pasteur does not have interchangeability data concerning alternate BCG products; therefore, we cannot make recommendations regarding substitution of one BCG product for another.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious or unexpected adverse reactions in patients receiving ImmuCyst® [Bacillus Calmette-Guérin (BCG), sub strain Connaught] should be reported to Sanofi Pasteur Limited or Health Canada.
Pharmacovigilance Department
Sanofi Pasteur Limited
1755 Steeles Avenue West, Toronto, Ontario, Canada M2R 3T4
Telephone: 1-888-621-1146 or Fax: 416-667-2435
To correct your mailing address or fax number, contact Sanofi Pasteur Limited.
To report suspected adverse reactions to these or other health products, please contact Health Canada's Canada Vigilance Program toll-free at 1-866-234-2345, or visit the MedEffect™ Canada Web site for information on how to report.
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction Reporting section. The Reporting Form is also in the Canadian Compendium of Pharmaceuticals and Specialties.
For other health product inquiries related to this communication, please contact Health Canada at:
Biologics and Genetic Therapies Directorate
E-mail: bgtd_ora@hc-sc.gc.ca
Telephone: 613-957-1722
Fax: 613-946-9520
original signed by
G. Eileen Macallum, D.V.M.
Vice President Industrial Operations